Prelude Therapeutics Inc Quarterly Debt-to-equity in % from Q2 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Prelude Therapeutics Inc quarterly Debt-to-equity history and growth rate from Q2 2021 to Q3 2024.
  • Prelude Therapeutics Inc Debt-to-equity for the quarter ending September 30, 2024 was 20.3 %, a 104% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 20.3 +10.3 +104% Sep 30, 2024
Q2 2024 16 +5.26 +48.8% Jun 30, 2024
Q1 2024 12.2 +1.2 +10.9% Mar 31, 2024
Q4 2023 11.2 +1.71 +18% Dec 31, 2023
Q3 2023 9.98 +1.9 +23.5% Sep 30, 2023
Q2 2023 10.8 +3.84 +55.4% Jun 30, 2023
Q1 2023 11 +4.86 +79.2% Mar 31, 2023
Q4 2022 9.51 +4.26 +81.1% Dec 31, 2022
Q3 2022 8.07 +3.14 +63.7% Sep 30, 2022
Q2 2022 6.93 +2.4 +53% Jun 30, 2022
Q1 2022 6.14 Mar 31, 2022
Q4 2021 5.25 Dec 31, 2021
Q3 2021 4.93 Sep 30, 2021
Q2 2021 4.53 Jun 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.